Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prasinezumab (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Neotope Biosciences; Prothena

    • Most Recent Events

    • 18 Sep 2022 Results by deriving data from NCT02095171, NCT03100149, NCT04777331 and PPMI; developing Roche Digital Health Technology Platform to assess Disease Severity and Progression in Individuals with Parkinsons Disease, presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
    • 13 Dec 2016 Results published in the Prothena Corporation Media Release.
    • 13 Dec 2016 According to Prothena Corporation media release, clinical results were published in Movement Disorders Journal.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top